# Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

> **NCT02984852** · PHASE1 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Darunavir (DRV)
- **DRUG:** Cobicistat (COBI)
- **DRUG:** Emtricitabine (FTC)
- **DRUG:** Tenofovir Alafenamide (TAF)

## Key facts

- **NCT ID:** NCT02984852
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02984852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02984852, "Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02984852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*